CURIGIN
LIVE

Serial Number

79288213

Owner

Curigin Co., Ltd

Attorney

Eric S. Hyman

Filing Date

Apr 21, 2020

Add to watchlist:

No watchlists yet
View on USPTO

CURIGIN Trademark

Serial Number: 79288213 • Registration: 6585328

CURIGIN is a trademark filed by Curigin Co., Ltd on April 21, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Curigin Co., Ltd

506, 31, Ttukseom-ro 1-gil,

Entity Type: 03

Trademark Details

Filing Date

April 21, 2020

Registration Date

December 14, 2021

Published for Opposition

September 28, 2021

Goods & Services

Biopharmaceuticals for the prevention of cancer; biopharmaceuticals for the diagnosis of cancer; biopharmaceuticals for the treatment of cancer; biopharmaceuticals in the form of cancer oncolytic virus for the prevention of cancer; biopharmaceuticals in the form oncolytic virus for the diagnosis of cancer; biopharmaceuticals in the form of oncolytic virus for the treatment of cancer; Drugs for medical purpose for the treatment of cancer and non-cancerous diseases, namely, respiratory, metabolic, neurological, ophthalmological, gastrointestinal, cardiovascular, skin, urogenital, gynecological, endocrine, head and neck, skeletal, autoimmune and rare diseases; Veterinary preparations for the treatment of cancer and non-cancerous diseases, namely, respiratory, metabolic, neurological, ophthalmological, gastrointestinal, cardiovascular, skin, urogenital, gynecological, endocrine, head and neck, skeletal, autoimmune and rare diseases; anti-cancer preparations; antiulcerants; vaccines; pharmaceutical preparations and substances for the prevention of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical compounds for treating cancer; pharmaceuticals for viral and non-viral vector-based gene therapy; medicine for viral and non-viral vector-based gene therapy for human purposes; antibiotics; dietary supplements; dietetic nutritionally fortified food adapted for medical purposes; insecticides; fungicides

Providing commercial information and consumer product information; import-export agency services; sales agency services, namely, sales promotion for others in the field of apparatus for use in medical analysis; arranging sales events for others in the field of apparatus for use in medical analysis; sales agency services, namely, sales promotion for others in the field of pharmaceuticals; arranging sales events for others in the field of pharmaceuticals; business intermediary services in the nature of purchasing pharmaceuticals for others relating to mail order by telecommunications; procurement of contracts for the purchase and sale of goods and services; advertising services; advertising services relating to pharmaceutical products; business intermediary services in the nature of matching purchasers with sellers of goods and services for the sale and purchase of goods and services

Providing health information, not including dentistry; healthcare information services relating to the use of medical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases; medical and pharmaceutical consultancy; consultancy services relating to pharmaceutical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases

Research relating to biotechnology; scientific research for medical purposes in the field of cancerous diseases; research relating to pharmaceuticals; research in the field of medical products; medical research services; conducting clinical trials for others; clinical studies in the nature of medical research; development of new technology for others in the field of biotechnology; scientific research for medical purposes in the area of cancerous diseases; development of medical products; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; conducting clinical research in the field of medicines; clinical trials of medicines, for others; software design and development; computer programming for others in the medical field

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 21, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 25, 2022 FICS
FINAL DISPOSITION PROCESSED
May 24, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 14, 2022 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 19, 2021 OPNX
REGISTERED-PRINCIPAL REGISTER
Dec 14, 2021 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 1, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 1, 2021 OPNR
NOTIFICATION PROCESSED BY IB
Oct 25, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 28, 2021 NPUB
PUBLISHED FOR OPPOSITION
Sep 28, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 22, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 22, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 8, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 25, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 25, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 25, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 25, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 25, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 9, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 9, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 8, 2021 GNFN
FINAL REFUSAL E-MAILED
Apr 8, 2021 GNFR
FINAL REFUSAL WRITTEN
Apr 8, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 25, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 25, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 25, 2021 TROA
REFUSAL PROCESSED BY IB
Sep 27, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 5, 2020 RFCS
REFUSAL PROCESSED BY MPU
Aug 25, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 19, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jul 18, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 13, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 30, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 26, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 25, 2020 REPR